{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:43:43Z","timestamp":1793371423741,"version":"4.5.0"},"reference-count":12,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Oncol"],"abstract":"<jats:p>Introduction: Patients undergoing maintenance hemodialysis exhibit a unique immunological state characterized by chronic inflammation and T-cell dysfunction. Evidence regarding the efficacy and safety of combination chemoimmunotherapy in dialysis patients remains extremely limited. Case Report: We report a case of extensive-stage small cell lung cancer (performance status 1, cT1cN2M1c, stage IVB) in a patient undergoing maintenance hemodialysis who received 4 cycles of carboplatin (300 mg\/m2, day 1), etoposide (50 mg\/m2, days 1 and 3), and durvalumab (1,500 mg\/body, day 1). Treatment was safely continued after adjusting the dosing schedule and dose levels in accordance with the dialysis schedule. Although new brain metastases developed during treatment and whole-brain radiotherapy was administered, computed tomography after 4 cycles demonstrated a partial response, and durvalumab maintenance therapy was subsequently continued. Grade 4 thrombocytopenia and grade 3 anemia and neutropenia were observed as adverse events; however, these were manageable with transfusion support and dose reduction. Disease progression was subsequently observed. Conclusion: Carboplatin, etoposide, and durvalumab can provide meaningful therapeutic benefit even in patients undergoing maintenance hemodialysis when adverse events are appropriately managed.<\/jats:p>","DOI":"10.1159\/000552719","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:00:47Z","timestamp":1785859247000},"page":"1740-1746","source":"Crossref","is-referenced-by-count":1,"title":["Carboplatin, Etoposide, and Durvalumab for Extensive-Stage Small Cell Lung Cancer in a Patient Undergoing Maintenance Hemodialysis: A Case Report"],"prefix":"10.1159","volume":"19","author":[{"given":"Morimi","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninso","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Fujisaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133759"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134301"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186533"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.02.451"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.741"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14166"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-023-00640-8"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh008"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408"}],"container-title":["Case Reports in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:01:50Z","timestamp":1791993710000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000552719","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.33154214","asserted-by":"subject"}]},"ISSN":["1662-6575"],"issn-type":[{"value":"1662-6575","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}